Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
| Autor: | Ali Roohbakhsh, Fatemeh Sadat Heydari, Simin Zare |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Gevokizumab
Myocarditis Interleukin-1beta Myocardial Infarction Bioinformatics 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine medicine Humans Pericarditis Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Anakinra business.industry Antibodies Monoclonal Endothelial Cells medicine.disease Review article Clinical trial Rilonacept Interleukin 1 Receptor Antagonist Protein Canakinumab Cardiovascular Diseases 030220 oncology & carcinogenesis Rheumatoid arthritis business medicine.drug |
| Zdroj: | Current Reviews in Clinical and Experimental Pharmacology. 16:219-227 |
| ISSN: | 2772-4328 |
| DOI: | 10.2174/1574884715666200716145935 |
| Popis: | Background: Interleukin-1 (IL-1) is a pro-inflammatory cytokine that is produced by endothelial cells, smooth muscle cells, and macrophages. It is an important regulator of a complex humoral and cellular inflammatory response. IL-1β is known to be implicated in the development of chronic inflammatory disorders such as rheumatoid arthritis. We aimed to review the effects of IL-1β antagonists in various cardiovascular disorders and to discuss their effectiveness in such diseases. Methods: Major biomedical databases, including PubMed and Scopus, were searched for clinical studies regarding the treatment of cardiovascular diseases (CVD) using IL-1β antagonists. Results: The drugs currently used in clinical trials are anakinra, the monoclonal antibodies canakinumab and gevokizumab, and the soluble decoy receptor rilonacept. There are clinical trials and case reports of patients with CVD in which anakinra administration, at the standard dose, has caused rapid clinical improvement and recovery in a few months. Our comprehensive search revealed that IL-1β antagonists have beneficial effects in the treatment of various cardiovascular disorders such as myocarditis, pericarditis, heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, and Kawasaki disease. Conclusion: The present review article shows that IL-1β has a major role in the pathophysiology of cardiovascular disorders, its antagonists have beneficial effects in these conditions, and their use should be considered in future studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|